Accelerator mass spectrometry analysis of 14C-oxaliplatin concentrations in biological samples and 14C contents in biological samples and antineoplastic agents

Abstract Accelerator mass spectrometry (AMS) is expected to play an important role in microdose trials. In this study, we measured the 14 C concentration in 14 C-oxaliplatin-spiked serum, urine and supernatant of fecal homogenate samples in our Yamagata University (YU) – AMS system. The calibration curves of 14 C concentration in serum, urine and supernatant of fecal homogenate were linear (the correlation coefficients were ⩾0.9893), and the precision and accuracy was within the acceptance criteria. To examine a 14 C content of water in three vacuum blood collection tubes and a syringe were measured. 14 C was not detected from water in these devices. The mean 14 C content in urine samples of 6 healthy Japanese volunteers was 0.144 dpm/mL, and the intra-day fluctuation of 14 C content in urine from a volunteer was little. The antineoplastic agents are administered to the patients in combination. Then, 14 C contents of the antineoplastic agents were quantitated. 14 C contents were different among 10 antineoplastic agents; 14 C contents of paclitaxel injection and docetaxel hydrate injection were higher than those of the other injections. These results indicate that our quantitation method using YU-AMS system is suited for microdosing studies and that measurement of baseline and co-administered drugs might be necessary for the studies in low concentrations.